atezolizumab + capecitabine

Atezolizumab + capecitabine is a **combination therapy** consisting of two anticancer agents: atezolizumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death ligand 1 (PD-L1), and capecitabine, an orally administered prodrug of 5-fluorouracil (5-FU) that impedes cancer cell proliferation by inhibiting thymidylate synthase. This drug combination is being studied for use in various cancers, such as triple-negative breast cancer and metastatic colorectal cancer, aiming to combine the immunotherapeutic effect of atezolizumab with the cytotoxic effect of capecitabine. The combination is being evaluated in clinical trials for its safety and efficacy, particularly as adjuvant or post-neoadjuvant therapy in patients with residual disease or refractory conditions[4][1][5].